University of Warwick wins first Domainex Discovery STAR Award

To support the search for a new treatment for Chagas disease

Professor Vilmos Fulop of the University of Warwick in the UK is the recipient of the first Domainex Discovery STAR Award.

This award will give Professor Fulop access to Domainex’s drug discovery capabilities to support his research for a new treatment for Chagas disease. No financial details have been released.

'Domainex received many strong applications to its Discovery STAR award scheme, but Professor Fulop’s project stood out as he had all the elements needed to start a drug discovery project in this area of unmet medical need,' said Eddy Littler, Chief Executive of Domainex. 'We very much look forward to helping Professor Fulop to identify inhibitors of his drug target, and hope that in doing so he will be able to access further funding that will support our joint efforts towards finding a new cure for this terrible disease.'

Domainex will provide Professor Fulop with drug discovery guidance and exclusive access to its LeadBuilder virtual hit screening technology.

Following the identification of hits using this approach, Professor Fulop will seek additional funding to progress his work.

I regard this collaboration as a starting point towards making significant steps in finding a new cure for the treatment of neglected Chagas

Professor Fulop said: ‘I am absolutely delighted with this award and looking forward to working with Domainex. I regard this collaboration as a starting point towards making significant steps in the finding of a new cure for the treatment of neglected Chagas and the related African sleeping sickness disease.’

Domainex launched its Discovery STAR Award to support early drug discovery. The scheme provides successful applicants with virtual hit screening using Domainex’s LeadBuilder platform and/or drug discovery consultancy services. The aim is to bridge a current ‘funding gap’ for these activities, thereby allowing projects to progress to a point that is suitable for larger external grant-funding schemes such as the TSB/MRC Biomedical Catalyst Fund, The Wellcome Trust’s SDDI scheme, European Union FP7, and MRC DPFS.

Domainex is based on the Cambridge Science Park, UK and has offices in the London Bioscience Innovation Centre.

You may also like

Research & Development

Adenosine A2a receptor: novel biophysical fragment screening using polymer-encapsulated nanodiscs

Fragment screening is a useful method for hit identification as it offers an efficient and flexible way to identify novel therapeutic starting points that other techniques may have missed because of the small molecular size of the fragments
Design & Build

New biology centre opened by HM Lord-Lieutenant of Cambridgeshire

The new three-storey facility provides over 24,000 sqft for Domainex’s expanding biology/bioanalytical departments
Research & Development

Domainex opens dedicated facility at Unity Campus

“The investment into our new facility has allowed us to create a fully dedicated suite of labs to conduct our biology services”
Drug Delivery

Parkinson’s UK and Domainex collaborate on inflammation therapy

The organisations plan to develop therapies targeting neuroinflammation to slow the progression of Parkinson’s
Research & Development

Queen’s University Belfast enters FLIP inhibitor collaboration

The university will work with Ipsen on the inhibitors, which have been supported by Domainex
Research & Development

Expanding the medicinal chemist’s toolbox

Ray Boffey, Executive Director of Medicines Research at Domainex, explains the applications and benefits of fragment-based drug discovery, fragment hit expansion and the use of flow chemistry
Research & Development

Apeiron and Domainex partner to progress drug discovery

The companies have previously collaborated on hit identification, both fragment-based and virtual screening
Subscribe now